Poznan University of Medical Sciences
Poznan, 60-806, Poland
NCT Number: NCT04939870
The studies included the effect of chronic kidney disease advancement on the accumulation of oxidative stress markers in plasma. In patients with end-stage renal disease, the effect of replacement therapy was also assessed. Therefore, the patient with chronic kidney disease was evaluated divided into three groups (chronic kidney disease at stage G3b-G4, peritoneal dialysis, hemodialysis). In addition, changes in the interrelationship between oxidative modifications, carbonyl and nitrogen stress, and the carbamylation resulting from the progression of kidney disease have been taken into account. This issue is related to the assessment of whether the protein modification types differentiate patients depending on the stage of chronic kidney disease and the method of renal replacement therapy. Protein modifications associated with oxidative stress are a part of the complications resulting from chronic kidney diseases, such as malnutrition, chronic inflammation, dyslipidemia, iron disorder, and calcium and phosphate disorders. Also, diseases of atherosclerosis aetiology are much higher frequency in patients with chronic kidney disease than in those with normal kidney function. Therefore, in the studies presented here, particular attention was paid to the effect of oxidative stress on chronic kidney disease complications in the aspect of cardiovascular damage. The specificity of atherosclerosis in patients with chronic kidney disease was evaluated by comparing groups of this type of patients with patients with ischemic heart diseases and normal renal function.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Poznan, 60-806, Poland
Redox imbalance in the course of CKD results in the intensification of oxidative and carbonyl stress, which leads to the modification of many molecules, including proteins necessary for the proper functioning of the body. The assessment of the accumulation of modified proteins in the plasma is not only an indirect indicator of the severity of redox imbalance in the system, but also allows the analysis of the influence of oxidative stress and its derivatives (glycation, carbonyl stress and carbamylation) on the pathogenesis of CKD. In addition, compounds formed as a result of the action of ROS on proteins may affect the development of long-term consequences of CKD, such as chronic inflammation, dyslipidemia, renal osteodystrophy, iron metabolism disorders and malnutrition. On the other hand, complications in patients with CKD may influence the intensification of oxidative modifications of proteins.
The following goals were set in the study:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
The following criteria of qualifying for the study were adopted for all respondents:
In addition, for CKD patients, the following additional inclusion conditions were applied:
At the same time, depending on the technique of renal replacement therapy used, additional inclusion criteria were established for each of the subgroups:
in group HD:
For CARD patients, additional conditions include:
In turn, for the HV group, additional conditions include:
selected biochemical parameters
Time frame: 4 years
The number of laboratory parameters were determined in all groups:
Time frame: 4 years
CML [µg/mg protein], CEL [µg/mg protein], MG [µg/mg protein], AGE [µg/mg protein], RAGE [µg/mg protein] 3-NT [µmol/mg protein], AOPP [µmol/mg protein], carbonyl protein groups [nmol/mg protein], carbamyl protein groups [µg/mg protein]
Time frame: 4 years
age [years], sex [number of female and male [n]] were recorded in all groups
Poznan University of Medical Sciences
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05214872
Arterial Occlusive Diseases, Arteriosclerosis
Poznan, Poland
View Trial DetailsNCT06545461
Acid-Base Imbalance, Acidosis
View Trial DetailsNCT06046924
Albuminuria, Cardiovascular Diseases
View Trial DetailsNCT05189847
Acute Coronary Syndrome, Acute Stroke
Moscow, Russia
View Trial Details